The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention also relates to infusion solutions of gemifloxacin and to processes for their preparation. Thus, 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-...

The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention also relates to infusion solutions of gemifloxacin and to processes for their preparation. Thus 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1...

PURPOSE: A quinolones antibiotics having 7-(4-aminomethyl-3-oxime)pyrolidine substituent is provided to treat neutropenia. CONSTITUTION: A therapeutic agent for neutropenia contains effective amount of compound of chemical formula 1 pharmaceutically acceptable salt thereof solvate containign hydrate ester steriochemical isomer or precursor as an active ingredient. The compound of chemical formula 1 is gemifloxacin. The neutropenia is caused from a patient with adult acute myeoloid leukemia who t...

The present invention provides novel crystalline sesquihydrate form 1, sesquihydrate form 2, anhydrous form 3 and anhydrous form 4 of gemifloxacin mesylate, processes for their preparation and pharmaceutical compositions containing them. The present invention also provides gemifloxacin mesylate acetic acid solvate, gemifloxacin mesylate N-methylpyrrolidone solvate and gemifloxacin mesylate 1,4-dioxane solvate;and processes for their preparation.

The present invention provides a novel process for the preparation of gemifloxacin and its pharmaceutically acceptable acid addition salts in high yield. The present invention also relates to novel polymorphs of gemifloxacin free base and its hydrates to the processes for their preparation and to pharmaceutical compositions comprising them. The present invention also relates to infusion solutions of gemifloxacin and to processes for their preparation. Thus 7-chloro-1-cyclopropyl-6-fluoro-4-oxo-1...

This invention relates in part to newly identified methods of using quinolone antibiotics particularly a gemifloxacin compound against atypical upper respiratory pathogenic bacteria

The present invention relates to a process for preparing acid salts of Gemifloxacin a quinolone type antibiotic agent having potent antimicrobial activity. The process according to the present invention can provide advantages such as simplicity of process improvement of productivity and improvement of yield and the like by reducing conventional three-step process to two-step process.

The present invention relates to novel crystalline forms of 1-cyclopropyl-y-chloro-ό- fluoro-4-oxo-14-dihydro[18]-naphthyridine-3-carboxylic acid mesylate salt (Gemifloxacin mesylate) hereafter designated as Gemifloxacin mesylate polymorphic Forms-H I J K L and M and process for the preparation thereof.